AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, announced the closing of an oversubscribed and upsized $315 million Series D financing. The round was led by Ally Bridge Group and co-led by Alpha Wave, alongside new investors Bain Capital Life Sciences, Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, Inc., a leading sovereign wealth fund, Eventide Asset Management, and Velosity Capital, with existing investors including Morningside, Eli Lilly and Company, SV Health Investors, Sanofi Ventures, Abingworth, SymBiosis, Tenmile, Brandon Capital, Piper Heartland, Catalio Capital Management, Proto Axiom, and Time BioVentures also participating.
AdvanCell has built a vertically integrated platform centered on proprietary Lead-212 technology that combines secure isotope supply, automated manufacturing, and scalable production to accelerate the development and commercial delivery of next-generation targeted alpha therapies. The financing will advance ADVC001 toward Phase 3 clinical development in metastatic prostate cancer, expand AdvanCell’s Lead-212 platform, strengthen isotope supply, expand U.S. manufacturing infrastructure, and accelerate the company’s growing pipeline of targeted alpha therapies.
AdvanCell’s lead program, ADVC001, is an investigational Lead-212 PSMA-targeted alpha therapy for metastatic prostate cancer currently in Phase 2 clinical development, designed to selectively deliver potent alpha radiation to tumor cells while minimizing radiation exposure to healthy tissue. The therapy has demonstrated encouraging Phase 1b anti-tumor activity and favorable tolerability in patients with prostate cancer, supporting its continued advancement while validating AdvanCell’s broader pipeline of next-generation targeted alpha therapies across additional cancer indications.
Concurrent with the financing round, Andrew Lam of Ally Bridge Group and Nik Economopoulos of Alpha Wave will join AdvanCell’s Board of Directors. Ally Bridge Group, founded in 2013, has led or co-led over $8 billion in healthcare transactions, while Alpha Wave is a global alternative asset manager with investments including SpaceX, Anthropic, OpenAI, Cerebras, TikTok, and HistoSonics.
KEY QUOTES:
“This financing marks a transformational milestone for AdvanCell and reflects the conviction of an exceptional investor syndicate in the potential of ADVC001 and the innovation behind our vertically integrated Lead-212 platform.”
“Building on our recent leadership appointments and U.S. expansion, this financing puts us in a strong position to enter our next stage of growth and execution, advancing our lead therapy ADVC001 toward registrational development, expanding isotope supply and manufacturing infrastructure to support Phase 3 and future commercial demand, and progressing our Lead-212 pipeline into the clinic.”
Philina Lee, Ph.D., Chief Executive Officer, AdvanCell
“The companies poised to lead the next generation of targeted alpha therapies will be those that combine differentiated clinical assets with end-to-end control over supply and manufacturing.”
“AdvanCell has assembled that foundation through its de-risked lead program, vertically integrated platform and experienced leadership team, uniquely positioning the company to execute at scale and emerge as a potential category leader.”
Andrew Lam, PharmD, Managing Director, Head of Biotech Private Equity, Ally Bridge Group
“The most enduring healthcare companies combine breakthrough science with the infrastructure and expertise to repeatedly develop new medicines.”
“We believe AdvanCell is building that kind of generational company, with the platform, manufacturing capabilities and pipeline to unlock the full potential of targeted alpha therapies.”
Nik Economopoulos, Director, Life Sciences Investments, Alpha Wave
